AKB-6899 NEW
| Price | $71 | $172 | $276 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-01 |
Product Details
| Product Name: AKB-6899 | CAS No.: 1007377-55-0 |
| Purity: 97.87% | Supply Ability: 10g |
| Release date: 2026/06/01 |
Product Introduction
Bioactivity
| Name | AKB-6899 |
| Description | AKB-6899 is an inhibitor of prolyl hydroxylase domain 3 (PHD3) and increases the soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages. AKB-6899 leads to stabilization of HIF-2α which induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth. |
| In vitro | In murine bone marrow-derived macrophages, AKB-6899 (10 μM; 24 hours) increases the levels of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 shows no effect on HIF-1α accumulation or VEGF production[1]. |
| In vivo | In C57BL/6 mice injected with B16F10 murine melanoma cells, AKB-6899 (17.5 mg/kg; i.p.) significantly reduces tumor growth[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (11.37 mM), Sonication is recommended. DMSO : 95 mg/mL (327.3 mM), Sonication is recommended. |
| Keywords | VEGFR1 | sVEGFR-1 | PHD3 | Inhibitor | inhibit | Hypoxia-inducible factors | HIFs | HIFProlylHydroxylase | HIF-PH | HIF-2α | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF | antitumor | antiangiogenic | AKB-6899 | AKB 6899 |
| Inhibitors Related | Ribociclib | Deferoxamine Mesylate | Dapagliflozin | Sorafenib | Glucosamine | glycine | Hydroxycitric acid tripotassium hydrate | Nintedanib esylate | Glucosamine hydrochloride | Chloramphenicol | Lenvatinib | Pazopanib |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Hematonosis Compound Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $100.00 |
HEBEI Meijinnong Import And Export Trade Co.,LTD
|
2022-10-14 | ||
| $10.00 |
Hebei Ningnan Trade Co. LTD
|
2022-10-14 | ||
| $20.00 |
Qiuxian Baitai New Material Co., LTD
|
2021-11-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY